VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Rizzo on Impact of Age on Survival Outcomes in MDS After HCT

J. Douglas Rizzo, MD, MS
Published: Thursday, Dec 31, 2015



J. Douglas Rizzo, MD, MS, assistant scientific professor, Center for International Blood and Marrow Transplant Research, professor of Medicine, Medical College of Wisconsin, discusses a study that examined if age affects survival outcomes in patients with myelodysplastic syndromes (MDS) who receive a hematopoietic cell transplant (HCT).

Hypomethylating agents can create disease modification for patients with MDS, Rizzo explains. However, allogeneic HCT has proven to be the only curative therapy for this disease.

In patients with MDS over the age of 65, Medicare coverage for HCT was found to be unavailable, Rizzo explains. In disagreement with this decision, researchers conducted a study comparing the survival outcomes of patients aged 55 to 64 with patients over 65, both of whom received HCT. Findings showed that there was not a higher 100-day mortality in the older patient population, Rizzo adds. The study demonstrates that age alone should not be a determinant when considering HCT for patients with MDS.


J. Douglas Rizzo, MD, MS, assistant scientific professor, Center for International Blood and Marrow Transplant Research, professor of Medicine, Medical College of Wisconsin, discusses a study that examined if age affects survival outcomes in patients with myelodysplastic syndromes (MDS) who receive a hematopoietic cell transplant (HCT).

Hypomethylating agents can create disease modification for patients with MDS, Rizzo explains. However, allogeneic HCT has proven to be the only curative therapy for this disease.

In patients with MDS over the age of 65, Medicare coverage for HCT was found to be unavailable, Rizzo explains. In disagreement with this decision, researchers conducted a study comparing the survival outcomes of patients aged 55 to 64 with patients over 65, both of whom received HCT. Findings showed that there was not a higher 100-day mortality in the older patient population, Rizzo adds. The study demonstrates that age alone should not be a determinant when considering HCT for patients with MDS.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x